Diagnostic and therapeutic technology assessment. Bacillus Calmette-Guerin immunotherapy in bladder cancer.
D000574:American Medical Association; D001500:BCG Vaccine / Q000009:adverse effects / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D013673:Technology Assessment, Biomedical; D014481:United States; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine